*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the "**U.S. Securities Act**") or any state securities law of the United States. The securities may not be offered or sold in the United States except pursuant to an exemption from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of securities in the United States.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated June 13, 2025 (the "**Prospectus**") issued by TransThera Sciences (Nanjing), Inc. (the "**Company**") for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.*

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

*In connection with the Global Offering, CLSA Limited, as stabilization manager (the "**Stabilization Manager**"), or its affiliates or any person acting for it, on behalf of the Underwriters, to the extent permitted by the applicable laws and regulatory requirements of Hong Kong or elsewhere, may effect transactions with a view to stabilizing or supporting the market price of the Shares at such price, in such amounts and in such manners as the Stabilization Manager, its affiliates or any person acting for it may determine and at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilization Manager (or its affiliates or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilization Manager (or its affiliates or any person acting for it) and in what the Stabilization Manager reasonably regards as the best interest of our Company, (b) may be discontinued at any time and (c) is required to be brought to an end on Friday, July 18, 2025, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Such stabilization action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).*

Potential investors should be aware that no stabilizing action can be taken to support the price of the Shares for longer than the stabilization period, which will begin on the Listing Date, and is expected to expire on Friday, July 18, 2025, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed "Underwriting — Underwriting Arrangements and Expenses — Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date.

TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	**:**	**15,281,000 H Shares**
Number of Hong Kong Offer Shares	**:**	**3,057,000 H Shares (as adjusted after reallocation)**
Number of International Offer Shares	**:**	**12,224,000 H Shares (as adjusted after reallocation)**
Offer Price	**:**	**HK$13.15 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Hong Kong Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong dollars and subject to refund)**
Nominal value	**:**	**RMB1.00 per H Share**
Stock code	**:**	**2617**

Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers

(In no particular order)

CITIC SECURITIES　华泰国际 HUATAI INTERNATIONAL

Overall Coordinator, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager

交銀國際 BOCOM International

Joint Bookrunners and Joint Lead Managers

中銀國際 BOCI　招銀国际 CMB INTERNATIONAL　浦銀國際 SPDB INTERNATIONAL　TradeGo Markets

TRANSTHERA SCIENCES (NANJING), INC. / 藥捷安康(南京)科技股份有限公司
ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

*Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 13 June 2025 (the "**Prospectus**") issued by TransThera Sciences (Nanjing), Inc. (the "**Company**").*

Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company information	
Stock code	2617
Stock short name	TRANSTHERA-B
Dealings commencement date	23 June 2025*

**see note at the end of the announcement*

Price Information	
Fixed Offer Price	HK$13.15
Offer Shares and Share Capital	
Number of Offer Shares	15,281,000
Final Number of Offer Shares in Hong Kong Public Offering	3,057,000
Final Number of Offer Shares in International Offering	12,224,000
Number of issued Shares upon Listing	396,897,633
Proceeds	
Gross proceeds (Note)	HK$ 200.95 million
Less: Estimated listing expenses payable based on Fixed Offer Price	HK$ (39.61) million
Net proceeds	HK$ 161.34 million

Note: Gross proceeds refers to the amount to which the issuer is entitled receive. For details of the use of proceeds, please refer to the Prospectus dated 13 June 2025.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	135,427
No. of successful applications	6,114
Subscription level	3,419.87 times
Claw-back triggered	No
No. of Offer Shares initially available under the Hong Kong Public Offering	1,528,500
No. of Offer Shares reallocated from the International Offering	1,528,500
Final no. of Offer Shares under the Hong Kong Public Offering (after reallocation)	3,057,000

% of Offer Shares under the Hong Kong Public Offering to the Global Offering	20.00%

Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can refer to https://www.hkeipo.hk/iporesult to perform a search by name or identification number or https://www.hkeipo.hk/iporesult for the full list of allottees.

INTERNATIONAL OFFERING

No. of placees	123
Subscription Level	0.97 times
No. of Offer Shares initially available under the International Offering	13,752,500
No. of Offer Shares reallocated to the Hong Kong Public Offering	1,528,500
Final no. of Offer Shares under the International Offering (after reallocation)	12,224,000
% of Offer Shares under the International Offering to the Global Offering	80.00%

The Directors confirm that, to the best of their knowledge, information and belief, save for (a) a consent under paragraph 5(2) of the Placing Guidelines granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the International Offering to close associates of existing Shareholders of the Company, and (b) a consent under paragraph 5(1) of the Placing Guidelines and Chapter 4.15 of the Guide in relation to allocation of Offer Shares to a connected client granted by the Stock Exchange, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Supervisors, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Supervisors, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Cornerstone Investors

Investor	***No. of Offer Shares allocated***	***% of Offer Shares***	***% of total issued H Shares after the Global Offering***	***% of total issued share capital after the Global Offering***	***Existing shareholders or their close associates***
Jiangbei Pharmaceutical Technology (Hong Kong) Limited / 江北醫藥科技(香港)有限公司	5,740,500	37.57%	1.90%	1.45%	Yes

Investor	*No. of Offer Shares allocated*	*% of Offer Shares*	*% of total issued H Shares after the Global Offering*	*% of total issued share capital after the Global Offering*	*Existing shareholders or their close associates*
Sinohsc Honest Limited / 華盛敦行有限公司	1,642,000	10.75%	0.54%	0.41%	Yes
Pharmablock Horizon Capital Limited/ 藥石地平線資本有限公司	821,500	5.38%	0.27%	0.21%	Yes
Kelingan (Hong Kong) Technology Co., Limited / 科瓴安(香港)科技有限公司	817,500	5.35%	0.27%	0.21%	No
AKESO,INC. / 康方生物科技(開曼)有限公司	752,500	4.92%	0.25%	0.19%	No
Total	9,774,000	63.96%	3.24%	2.46%	

Allotees with Waivers/Consents Obtained

Investor	*No. of Offer Shares allocated*	*% of total issued H Shares after the Global Offering*	*% of total issued share capital after the Global Offering*	*Relationship*
Allotees with consent under paragraph 5(2) of the Placing Guidelines in relation to subscription for Shares by close associates of existing Shareholders [Note 2]				
Jiangbei Pharmaceutical Technology Hong Kong Limited / 江北醫藥科技(香港)有限公司	5,740,500	1.90%	1.45% [Note 1]	A close associate of existing Shareholders and a Cornerstone Investor
Sinohsc Honest Limited / 華盛敦行有限公司	1,642,000	0.54%	0.41% [Note 1]	A close associate of existing Shareholders and a Cornerstone Investor
Pharmablock Horizon Capital Limited / 藥石地平線資本有限公司	821,500	0.27%	0.21% [Note 1]	A wholly-owned subsidiary of an existing Shareholder and a Cornerstone Investor

Investor	*No. of Offer Shares allocated*	*% of total issued H Shares after the Global Offering*	*% of total issued share capital after the Global Offering*	*Relationship*
Total	**8,204,000**	**2.72%**	**2.07%**	
Allotee with consent under paragraph 5(1) of the Placing Guidelines in relation to subscription for Shares by a connected client *Note 3*				
Huatai Capital Investment Limited	596,500	0.20%	0.15%	Connected client

Notes:

(1) Calculated based on the number of Offer Shares allocated to the respective Cornerstone Investors only, without taking into account the number of Shares held by the relevant existing Shareholders of whom such Cornerstone Investors are close associates.

*(2) Among the Cornerstone Investors, (i) Jiangbei Pharmaceutical Technology Hong Kong Limited is a close associate of Nanjing Zijin, Jiangbei Fund, Nanjing Qiruiyoukang, Jiangbei Assets Management, Taixing Qichen and Jiangsu Zhongde (each as defined in the Prospectus), which are existing Shareholders (together the "**Jiangsu Shareholders**"); (ii) Sinohsc Honest Limited is a close associate of Jiangsu Dunhe and Suzhou Dunxing (each as defined in the Prospectus), which are existing Shareholders; and (iii) Pharmablock Horizon Capital Limited is a wholly-owned subsidiary of PharmaBlock (as defined in the Prospectus), an existing Shareholder. The Stock Exchange has granted a consent under Paragraph 5(2) of the Placing Guidelines to permit H Shares in the International Offering to be placed to Jiangbei Pharmaceutical Technology Hong Kong Limited, Sinohsc Honest Limited and Pharmablock Horizon Capital Limited. Please refer to the section headed "Waivers from Strict Compliance with the Listing Rules and Exemption from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance – Cornerstone Subscription by Close Associates of Existing Shareholders" of the Prospectus for details.*

(3) For details, please refer to the section headed "Others/Additional Information – Placing to a connected client with a prior consent under paragraph 5(1) of the Placing Guideline" in this announcement.

Allotee who is customer or supplier of the Company

Investor	*No. of Offer Shares allocated*	*% of Offer Shares*	*% of total issued H Shares after the Global Offering*	*% of total issued share capital after the Global Offering*	*Relationship*
AKESO,INC. / 康方生物科技(開曼)有限公司	752,500	4.92%	0.25%	0.19%	Supplier of the Company and a Cornerstone Investor

LOCK-UP UNDERTAKINGS

Controlling Shareholders

Name	*Number of Shares held in the Company subject to lock-up undertakings upon listing*	*Number of H Shares held in the Company subject to lock-up undertakings upon listing*	*% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing*	*% of shareholding in the Company subject to lock-up undertakings upon listing)*	*Last day subject to the lock-up undertakings*
Frank Wu / 吳永謙 (“**Dr. Wu**”)[Note 1]	47,847,024	47,847,024	15.86%	12.06%	22 December 2025 (First Six-Month Period) [Note 2]
					22 June 2026 (Second Six Month Period) [Note 3]
Nanjing Yipu Bioscience Technology Partnership (Limited Partnership) / 南京益鏷生物科技合夥企業(有限合夥) (“**Nanjing Yipu**”)[Note 1]	54,726,152	27,363,076	9.07%	13.79%	22 December 2025 (First Six-Month Period) [Note 2]
					22 June 2026 (Second Six Month Period) [Note 3]
Nanjing Jiminrui Biotech Partnership (Limited Partnership) / 南京吉旻瑞生物科技合夥企業(有限合夥)(“**Nanjing Jiminrui**”)[Note 1]	28,284,453	5,387,697	1.79%	7.13%	22 December 2025 (First Six-Month Period) [Note 2]
					22 June 2026 (Second Six Month Period) [Note 3]
Subtotal	130,857,629	80,597,797	26.72%	32.98%	

Name	Number of Shares held in the Company subject to lock-up undertakings upon listing	Number of H Shares held in the Company subject to lock-up undertakings upon listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing)	Last day subject to the lock-up undertakings

Notes:

(1) As of the date of this announcement, Dr. Wu, Nanjing Yipu and Nanjing Jiminrui are the Controlling Shareholders of the Company, which are interested in approximately 34.29% of the total issued share capital of our Company. Please refer to the section headed "History, Development and Corporate Structure" in the Prospectus for details of the Controlling Shareholders.

(2) In accordance with the relevant Listing Rule/guidance materials, the required lock-up for the first six-month period ends on 22 December 2025. The Controlling Shareholder may dispose of or transfer Shares after the indicated date provided that the Controlling Shareholder will not cease to be a Controlling Shareholder, subject to compliance with applicable requirements under the PRC Company Law.

(3) In accordance with the relevant Listing Rule/guidance materials, the required lock-up for the second six-month period ends on 22 June 2026. The Controlling Shareholder may dispose of or transfer Shares after the indicated date provided that the Controlling Shareholder will not cease to be a Controlling Shareholder, subject to compliance with applicable requirements under the PRC Company Law.

Pre-IPO Investors (as defined in the "History, Development and Corporate Structure" section of the Prospectus)

Name	Number of Shares held in the Company subject to lock-up undertakings upon listing	Number of H Shares held in the Company subject to lock-up undertakings upon listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
Shanghai GP Healthcare Equity Investment Enterprise (Limited Partnership) / 上海金浦醫療健康股權投資合夥企業(有限合夥)[Note 1]	14,463,724	14,463,724	4.79%	3.64%	22 June 2026 [Note 2]
Shanghai GP Healthcare Phase III Venture Capital Fund Partnership (Limited Partnership) / 上海金浦健康三期創業投資	2,690,136	2,690,136	0.89%	0.68%	22 June 2026 [Note 2]

Name	Number of Shares held in the Company subject to lock-up undertakings upon listing	Number of H Shares held in the Company subject to lock-up undertakings upon listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
基金合夥企業(有限合夥) Note 1					
SDIC (Guangdong) Scientific and Technological Achievement Transformation Venture Capital Fund Partnership (Limited Partnership) / 國投(廣東)科技成果轉化創業投資基金合夥企業(有限合夥) Note 1	11,565,615	11,565,615	3.83%	2.91%	22 June 2026 Note 2
SDIC (Ningbo) Scientific and Technological Achievement Transformation Venture Capital Fund Partnership (Limited Partnership) / 國投(寧波)科技成果轉化創業投資基金合夥企業(有限合夥) Note 1	10,114,466	10,114,466	3.35%	2.55%	22 June 2026 Note 2
Shenzhen Linghui Cornerstone Equity Investment Fund Partnership (Limited Partnership) / 深圳市領匯基石股權投資基金合夥企業(有限合夥) Note 1	7,780,505	7,780,505	2.58%	1.96%	22 June 2026 Note 2
Wuhu Xingrui Cornerstone Equity Investment Partnership(Limited Partnership) / 蕪湖星睿基石股權投資合夥企業(有限合夥) Note 1	4,836,529	4,836,529	1.60%	1.22%	22 June 2026 Note 2
Nanjing Lingyi Cornerstone Equity Investment	2,494,369	2,494,369	0.83%	0.63%	22 June 2026 Note 2

Name	*Number of Shares held in the Company subject to lock-up undertakings upon listing*	*Number of H Shares held in the Company subject to lock-up undertakings upon listing*	*% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing*	*% of shareholding in the Company subject to lock-up undertakings upon listing*	*Last day subject to the lock-up undertakings*
Partnership (Limited Partnership) / (南京領益基石股權投資合夥企業(有限合夥) Note 1					
Shanghai Guohong Medical and Health Investment Center (Limited Partnership) / 上海國弘醫療健康投資中心(有限合夥) Note 1	6,857,315	6,857,315	2.27%	1.73%	22 June 2026 Note 2
Zhangjiagang Guohong Jiyuan Investment Partnership (Limited Partnership) / 張家港國弘紀元投資合夥企業(有限合夥) Note 1	4,045,823	4,045,823	1.34%	1.02%	22 June 2026 Note 2
Jingzhou Huikang Equity Investment Fund Partnership (Limited Partnership) / 荊州慧康股權投資基金合夥企業(有限合夥) Note 1	6,834,259	6,834,259	2.27%	1.72%	22 June 2026 Note 2
Structural Reform Fund, Shenzhen Guotiao Merchants and Equity Investment Fund Partnership (Limited Partnership) / 深圳國調招商併購股權投資基金合夥企業(有限合夥) Note 1	5,404,468	5,404,468	1.79%	1.36%	22 June 2026 Note 2
Nanjing Ennovation Raylight Venture Capital Partnership (Limited Partnership) / 南京恩然瑞光創業投資合夥企業(有限合夥) Note 1	3,337,787	1,668,894	0.55%	0.84%	22 June 2026 Note 2

Name	Number of Shares held in the Company subject to lock-up undertakings upon listing	Number of H Shares held in the Company subject to lock-up undertakings upon listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
Nanjing Qiruiyoukang Venture Capital Partnership (Limited Partnership) / 南京其瑞佑康創業投資合夥企業(有限合夥) Note 1	2,022,880	1,011,440	0.34%	0.51%	22 June 2026 Note 2
Taixing Qichen Emerging Industry Venture Capital Fund Partnership (Limited Partnership) / 泰興市啟辰新興產業創業投資基金合夥企業(有限合夥) Note 1	1,662,818	0	0.00%	0.42%	22 June 2026 Note 2
Jiangsu Zhongde Services Trade Industry Investment Fund (Limited Partnership) / 江蘇中德服貿產業投資基金(有限合夥) Note 1	831,409	0	0.00%	0.21%	22 June 2026 Note 2
Trinity Zhongzhi Phase II (Tianjin) Venture Capital Center (Limited Partnership) / 三一眾志二期(天津)創業投資中心(有限合夥) Note 1	2,718,707	2,718,707	0.90%	0.68%	22 June 2026 Note 2
Genecare Development Limited / 基科發展有限公司 Note 1	27,610,879	27,610,879	9.15%	6.96%	22 June 2026 Note 2
Future Industry Investment Fund II (Limited Partnership) / 先進製造產業投資基金二期(有限合夥) Note 1	24,274,756	24,274,756	8.05%	6.12%	22 June 2026 Note 2
CPE Investment (Hong Kong) 2021 Limited Note 1	21,521,091	0	0.00%	5.42%	22 June 2026 Note 2

Name	Number of Shares held in the Company subject to lock-up undertakings upon listing	Number of H Shares held in the Company subject to lock-up undertakings upon listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
China Structural Reform Fund Corporation Limited / 中國國有企業結構調整基金股份有限公司 Note 1	16,140,817	16,140,817	5.35%	4.07%	22 June 2026 Note 2
Nanjing Zijin Advanced Manufacture Industry Equity Investment Center (Limited Partnership) / 南京紫金先進製造產業股權投資中心(有限合夥) Note 1	11,245,844	11,245,844	3.73%	2.83%	22 June 2026 Note 2
Nanjing Jiangbei Medical Innovation Industry Fund (Limited Partnership) / 南京江北醫療創新產業基金(有限合夥) Note 1	7,620,244	3,810,122	1.26%	1.92%	22 June 2026 Note 2
Nanjing InnoMed Innovation & Entrepreneurship Investment Partnership (Limited Partnership) / 南京鷹盟創新創業投資合夥企業(有限合夥) Note 1	4,450,362	4,450,362	1.48%	1.12%	22 June 2026 Note 2
SIXTY DEGREE CAPITAL FUND II (INTERNATIONAL), L.P. Note 1	2,690,136	2,690,136	0.89%	0.68%	22 June 2026 Note 2
Nanjing Lvyong Ruihua Medical Health Equity Investment Partnership (Limited Partnership) / 南京綠涌瑞華醫健股權投資	2,494,369	2,494,369	0.83%	0.63%	22 June 2026 Note 2

Name	Number of Shares held in the Company subject to lock-up undertakings upon listing	Number of H Shares held in the Company subject to lock-up undertakings upon listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
合夥企業(有限合夥) Note 1					
CR Life Star Fund LLC Note 1	2,102,838	2,102,838	0.70%	0.53%	22 June 2026 Note 2
Eastern Handson Holdings Limited Note 1	1,941,690	1,941,690	0.64%	0.49%	22 June 2026 Note 2
Shanghai Guoxin Investment Development Co., Ltd. / 上海國鑫投資發展有限公司 Note 1	8,314,088	0	0.00%	2.09%	22 June 2026 Note 2
Nanjing Baiyide Equity Investment Partnership (Limited Partnership) / 南京百益德股權投資合夥企業(有限合夥) Note 1	1,662,818	831,409	0.28%	0.42%	22 June 2026 Note 2
Wuxi Ruitong Venture Capital Partnership (Limited Partnership) / 無錫瑞桐創業投資合夥企業(有限合夥) Note 1	831,409	831,409	0.28%	0.21%	22 June 2026 Note 2
Nanjing Jiangbei New Area State-owned Assets Management Co., Ltd. / 南京江北新區國有資產管理有限公司 Note 1	4,157,040	500,000	0.17%	1.05%	22 June 2026 Note 2
BOC Capital Investment Holdings Co., Ltd. / 中銀資本投資控股有限公司 Note 1	1,662,818	0	0.00%	0.42%	22 June 2026 Note 2
Jiangsu Dunhe Venture Capital Partnership (Limited Partnership) / 江蘇敦和創業投資合夥企業(有限合夥) Note 1	498,846	498,846	0.17%	0.13%	22 June 2026 Note 2

Name	*Number of Shares held in the Company subject to lock-up undertakings upon listing*	*Number of H Shares held in the Company subject to lock-up undertakings upon listing*	*% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing*	*% of shareholding in the Company subject to lock-up undertakings upon listing*	*Last day subject to the lock-up undertakings*
Suzhou Dunxing Jucai Venture Capital Partnership (Limited Partnership) / 蘇州敦行聚才創業投資合夥企業(有限合夥) Note 1	332,564	332,564	0.11%	0.08%	22 June 2026 Note 2
TIF Biomedical Fund II VCC Note 1	1,438,338	1,438,338	0.48%	0.36%	22 June 2026 Note 2
Subtotal	228,651,757	183,680,629	60.89%	57.61%	

Notes:

(1) Please refer to the section headed "History, Development and Corporate Structure — Pre-IPO Investments —Information about the Pre-IPO Investors" in the Prospectus for details of the Pre-IPO Investors.

(2) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.

Existing Shareholders (other than the Pre-IPO Investors as defined in the "History, Development and Corporate Structure" section of the Prospectus)

Name	*Number of Shares held in the Company subject to lock-up undertakings upon listing*	*Number of H Shares held in the Company subject to lock-up undertakings upon listing*	*% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing*	*% of shareholding in the Company subject to lock-up undertakings upon listing*	*Last day subject to the lock-up undertakings*
PharmaBlock Sciences (Nanjing), Inc. / 南京藥石科技股份有限公司	22,107,247	22,107,247	7.33%	5.57%	22 June 2026 Note 1
Subtotal	22,107,247	22,107,247	7.33%	5.57%	

Note:

(1) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.

Cornerstone Investors

Name	***Number of Shares held in the Company subject to lock-up undertakings upon listing***	***Number of H Shares held in the Company subject to lock-up undertakings upon listing*** *Note 1*	***% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing***	***% of shareholding in the Company subject to lock-up undertakings upon listing***	***Last day subject to the lock-up undertakings***
Jiangbei Pharmaceutical Technology Hong Kong Limited / 江北醫藥科技(香港)有限公司	5,740,500	5,740,500	1.90%	1.45%	22 December 2025 Note 1
Akeso, Inc. / 康方生物科技(開曼)有限公司	752,500	752,500	0.25%	0.19%	22 December 2025 Note 1
Sinohsc Honest Limited / 華盛敦行有限公司	1,642,000	1,642,000	0.54%	0.41%	22 December 2025 Note 1
Pharmablock Horizon Capital Limited / 藥石地平線資本有限公司	821,500	821,500	0.27%	0.21%	22 December 2025 Note 1
Kelingan (Hong Kong) Technology Co., Limited / 科瓴安(香港)科技有限公司	817,500	817,500	0.27%	0.21%	22 December 2025 Note 1
Subtotal	9,774,000	9,774,000	3.24%	2.46%	

Note:

(1) In accordance with the relevant cornerstone agreements, the required lock-up ends on 22 December 2025. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.

PLACEE CONCENTRATION ANALYSIS

Placees	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	5,740,500	46.96%	37.57%	36,618,522	9.23%
Top 5	9,774,000	79.96%	63.96%	63,590,679	16.02%
Top 10	11,776,500	96.34%	77.07%	65,593,179	16.53%
Top 25	12,147,000	99.37%	79.49%	65,963,679	16.62%

Notes

** Ranking of placees is based on the number of H Shares allotted to the placees.*

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued H Shares capital upon Listing	Number of Shares held upon Listing
Top 1	0	0.00%	0.00%	80,597,797	26.72%	130,857,629
Top 5	6,562,000	53.68%	42.94%	185,139,979	61.37%	248,041,533
Top 10	6,562,000	53.68%	42.94%	267,464,867	88.66%	338,680,509
Top 25	11,242,000	91.97%	73.57%	303,378,673	100.57%	375,425,724

Notes

** Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.*

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	0	0.00%	0.00%	80,597,797	130,857,629	32.97%
Top 5	5,740,500	46.96%	37.57%	179,365,092	250,580,734	63.13%
Top 10	6,562,000	53.68%	42.94%	255,226,140	347,962,873	87.67%
Top 25	10,370,500	84.84%	67.87%	302,507,173	397,738,133	100.21%

Notes

** Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.*

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

NO. OF H SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR
500	48,850	0 H Shares	0.80%
500	394	500 H Shares	
1,000	10,766	0 H Shares	0.54%
1,000	117	500 H Shares	
1,500	8,473	0 H Shares	0.43%
1,500	110	500 H Shares	
2,000	3,344	0 H Shares	0.36%
2,000	49	500 H Shares	
2,500	3,066	0 H Shares	0.32%
2,500	50	500 H Shares	
3,000	2,049	0 H Shares	0.29%
3,000	36	500 H Shares	
3,500	3,378	0 H Shares	0.27%
3,500	64	500 H Shares	
4,000	1,465	0 H Shares	0.24%
4,000	29	500 H Shares	
4,500	849	0 H Shares	0.23%
4,500	18	500 H Shares	
5,000	5,083	0 H Shares	0.21%
5,000	111	500 H Shares	
6,000	1,695	0 H Shares	0.19%
6,000	40	500 H Shares	
7,000	2,333	0 H Shares	0.18%
7,000	59	500 H Shares	
8,000	1,967	0 H Shares	0.16%
8,000	53	500 H Shares	
9,000	1,089	0 H Shares	0.15%
9,000	31	500 H Shares	
10,000	5,464	0 H Shares	0.14%
10,000	161	500 H Shares	
15,000	3,761	0 H Shares	0.11%
15,000	133	500 H Shares	
20,000	2,951	0 H Shares	0.10%
20,000	118	500 H Shares	
25,000	2,297	0 H Shares	0.09%
25,000	102	500 H Shares	
30,000	1,688	0 H Shares	0.08%

NO. OF H SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR
30,000	81	500 H Shares	
35,000	1,365	0 H Shares	0.07%
35,000	71	500 H Shares	
40,000	1,538	0 H Shares	0.06%
40,000	84	500 H Shares	
45,000	795	0 H Shares	0.06%
45,000	46	500 H Shares	
50,000	2,346	0 H Shares	0.06%
50,000	142	500 H Shares	
60,000	1,259	0 H Shares	0.05%
60,000	83	500 H Shares	
70,000	1,170	0 H Shares	0.05%
70,000	82	500 H Shares	
80,000	1,036	0 H Shares	0.04%
80,000	78	500 H Shares	
90,000	578	0 H Shares	0.04%
90,000	46	500 H Shares	
100,000	2,425	0 H Shares	0.04%
100,000	200	500 H Shares	
150,000	1,350	0 H Shares	0.03%
150,000	135	500 H Shares	
200,000	972	0 H Shares	0.03%
200,000	111	500 H Shares	
250,000	720	0 H Shares	0.02%
250,000	92	500 H Shares	
300,000	441	0 H Shares	0.02%
300,000	62	500 H Shares	
350,000	457	0 H Shares	0.02%
350,000	69	500 H Shares	
400,000	971	0 H Shares	0.07%
400,000	1,238	500 H Shares	
450,000	131	0 H Shares	0.06%
450,000	170	500 H Shares	
500,000	290	0 H Shares	0.06%
500,000	383	500 H Shares	
600,000	157	0 H Shares	0.05%
600,000	215	500 H Shares	
700,000	85	0 H Shares	0.04%
700,000	120	500 H Shares	
764,000	659	0 H Shares	0.04%
764,000	931	500 H Shares	
Total	135,427	3,057,000 H Shares	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's shares.

The Directors confirm that, to the best of their knowledge, no rebate has been, directly or indirectly, provided by the issuer, its controlling shareholder(s), directors or syndicate members to any placees or the public (as the case may be) and the consideration payable by them for each share (or, where applicable, each unit of other equity securities or interests (which include equity securities, interests in a REIT, stapled securities and securities of an investment company (as defined in rule 21.01)) of the issuer subscribed for or purchased by them is the same as the final offer price determined by the issuer, in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

OTHERS/ADDITIONAL INFORMATION

Reallocation

As the International Offer Shares are undersubscribed and the Hong Kong Public Offer Shares are oversubscribed, the reallocation procedure as disclosed in the section headed "Structure of the Global Offering — The Hong Kong Public Offering — Reallocation" of the Prospectus has been applied.

As a result of such reallocation, the final number of Offer Shares under the Hong Kong Public Offering is adjusted to 3,057,000 H Shares, representing two times of the initial number of Offer Shares under the Hong Kong Public Offering.

Placing to a connected client with a prior consent under paragraph 5(1) of the Placing Guidelines

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate certain Offer Shares in the International Offering to a connected client listed below. The allocation of Offer Shares to such connected client is in compliance with all the conditions under the consent granted by the Stock Exchange.

Connected Distributor	Connected Client/ Placee	Relationship with the Connected Distributor	Whether the connected client will hold beneficial interests of Offer Shares on a non-discretionary or discretionary basis for	Number of Offer Shares to be subscribed	Approximate % to the Offer Shares under the Global Offering	Approximate % to the total issued share capital immediately following completion of the Global Offering

			independent third parties			
Huatai Financial Holdings (Hong Kong) Limited ("**Huatai**")	Huatai Capital Investment Limited ("**HTCI**")	Huatai and HTCI are fellow subsidiaries of Huatai Securities Co., Ltd.	Non-discretionary basis	596,500	3.90%	0.15%

Note: *HTCI will hold the Offer Shares on behalf of its underlying client. To the best knowledge of HTCI after due enquiry, the underlying client of HTCI is an independent third party of HTCI and Huatai and the companies which are members of the same group of companies as Huatai.*

Allocations of Offer Shares to close associates of existing Shareholders and Cornerstone Investors with a consent under paragraph 5(2) of the Placing Guidelines

The Company has applied to, and the Stock Exchange has granted, a consent under paragraph 5(2) of the Placing Guidelines for permitting the Company to allocate Offer Shares in the International Offering to certain close associates of existing shareholders as cornerstone investors, subject to the following conditions:

(a) the Company will comply with the public float requirements of Rules 8.08(1) and 18A.07 of the Listing Rules;

(b) the Offer Shares to be subscribed by and allocated to each of Jiangbei Pharmaceutical, Sinohsc Honest and Pharmablock Horizon as Cornerstone Investors under the Global Offering will be at the same Offer Price and on substantially the same terms as, or no more favorable than, the terms of other cornerstone investors (including being subject to a lock-up period of six months from the Listing Date) and each of Jiangbei Pharmaceutical, Sinohsc Honest and Pharmablock Horizon shall pay and settle in full the consideration for the relevant Offer Shares before dealings commence on the Listing Date;

(c) the Company and the Joint Sponsors confirm that no preferential treatment has been, nor will be, directly or indirectly, given to each of Jiangbei Pharmaceutical, Sinohsc Honest and Pharmablock Horizon as Cornerstone Investors by virtue of its relationship with the Company in any allocation in the Global Offering, other than the preferential treatment of assured entitlement under the Proposed Cornerstone Investments which follows the principles set out in the Chapters 2.3 and 4.15 of the Guide; and

(d) details of the subscription of the Offer Shares by each of Jiangbei Pharmaceutical, Sinohsc Honest and Pharmablock Horizon as Cornerstone Investors under the Global Offering are disclosed in this prospectus, and details of the allocation will be disclosed in the allotment results announcement of our Company.

Such allocations of Offer Shares are in compliance with all the conditions under the consent granted by the Stock Exchange. For details of the allocations of Offer Shares to existing Shareholders and Cornerstone Investors, please refer to the section headed " Allotment Results Details – International Offer – Allotees with Waivers/Consents Obtained" in this announcement.

DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.
The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated 13 June 2025 issued by TransThera Sciences (Nanjing), Inc. for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.
**Potential investors of the Offer Shares should note that the Joint Representatives (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed "Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on 23 June 2025).*

PUBLIC FLOAT

Immediately following the completion of the Global Offering, an aggregate of 221,068,876 H Shares or approximately 55.70% of the total issued share capital of the Company will be held in the public hands. Therefore, the number of H Shares in the public hands represents no less than 25% of the total issued share capital of the Company, satisfying the minimum percentage requirement in compliance with Rule 8.08(1) of the Listing Rules. The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders do not hold more than 50% of the Shares held in the public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, June 23, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the paragraph headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination" in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk. Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Monday, June 23, 2025 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Monday, June 23, 2025 (Hong Kong time).

The H Shares will be traded in board lots of 500 H Shares each, and the stock code of the H Shares will be 2617.

By order of our Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, June 20, 2025

The directors of the Company named in the application to which this announcement relates are: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin and Dr. Yi Hua as non-executive directors; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.